Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 4.48B | 7.3% |
| Gross Profit | 2.3B | 9.6% |
| Cost of Revenue | 2.18B | 4.9% |
| Operating expense | 1.42B | 13.7% |
| Net Income | 433M | 53.5% |
| EBITDA | 1.11B | 68.3% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 39.9B | 0.7% |
| Total Liabilities | 32.6B | 2.1% |
| Total Equity | 7.25B | 6.2% |
| Shares Outstanding | 1.16B | 0.3% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | 369M | 62.6% |
| Cash from investing | 135M | 42.8% |
| Cash from financing | -453M | 7650% |
EPS
Financial Highlights for Teva Pharmaceutical in Q3 '25
Teva Pharmaceutical reported a revenue of 4.48B, which is a 7.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.3B, marking a 9.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.18B, a 4.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.42B, showing a -13.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 433M, showing a 53.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 1.11B, showing a 68.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Teva Pharmaceutical with growth in revenue, gross profit, and net income.
